FDA is recommending new safety measures to improve the safe use of long acting beta agonists (LABAs).
New Safe Use Requirements for Long-Acting Beta-Agonists (LABAs)

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
FDA is recommending new safety measures to improve the safe use of long acting beta agonists (LABAs).
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
IgG4-RD Case Conversations: Systemic Disease Infiltrating the Skull Base
IgG4-RD Case Conversations: Using Thoracic CT as a Diagnostic Clue
IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement
HF Management for Patients with Comorbid Conditions
Level Up Your Skills: Tailoring Management of HF
HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
Second-line Chemotherapy Options in Metastatic PDAC
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?